NEWHALL CHARLES W III

CIK 000100554434 companiesBALTIMORE, MD

SEC Profile

Transactions

Companies

Filings

CIK

0001005544

Recent Transactions

50 trades

Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-11-21$12.98/sh+15,000→ 119,644 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2025-11-21−15,000→ 0 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-10-09$51.55/sh−1,200→ 104,644 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-10-09$50.73/sh−23,800→ 105,844 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-08-27$45.01/sh−3,588→ 129,644 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-08-25$45.00/sh−1,000→ 133,232 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-08-22$45.00/sh−1,412→ 134,232 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-02-22+5,369→ 135,644 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2025-02-22−5,369→ 0 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2025-02-19+4,475→ 4,475 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2025-02-19+7,296→ 7,296 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2024-11-11$9.13/sh+20,000→ 140,975 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2024-11-11$36.24/sh−10,700→ 130,275 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2024-11-11−20,000→ 0 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2024-02-23−3,886→ 0 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2024-02-23+3,886→ 120,975 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2024-02-22+8,252→ 8,252 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2024-02-22+5,369→ 5,369 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2023-11-16$9.24/sh+7,457→ 119,589 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2023-11-16−7,457→ 0 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2023-11-16$28.01/sh−2,500→ 117,089 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2023-02-23+3,886→ 3,886 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2023-02-23+6,293→ 6,293 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2023-02-22+3,882→ 112,132 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2023-02-22−3,882→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2022-12-28−8,722→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2022-12-28$7.90/sh+8,722→ 110,453 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2022-02-22+6,847→ 6,847 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2022-02-22+3,882→ 3,882 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2022-02-19+4,222→ 101,731 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2022-02-19−4,222→ 0 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2021-02-19+7,365→ 7,365 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2021-02-19+4,222→ 4,222 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2020-02-21$23.99/sh+5,211→ 97,509 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2020-02-21+9,305→ 9,305 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2019-02-22+12,427→ 12,427 total
Gift
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2018-04-17−2,203→ 108,250 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2018-02-23+8,613→ 8,613 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2017-06-13+6,036→ 6,036 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2017-02-24+7,905→ 7,905 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2016-03-01+15,000→ 15,000 total
Other
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2015-12-03+33,127→ 92,298 total
Other
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2015-11-11+33,159→ 59,171 total
Other
Vitae Pharmaceuticals, Inc
Common Stock
2015-07-01+289→ 289 total
Other
Vitae Pharmaceuticals, Inc
Common Stock
2015-07-01+289→ 289 total
Other
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2015-06-15+26,012→ 26,012 total
Award
Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy)
2015-05-28+10,000→ 10,000 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2015-03-03+20,000→ 20,000 total
Award
Vitae Pharmaceuticals, Inc
Stock Option (Right to Buy)
2014-09-24+17,000→ 17,000 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2014-01-21+7,457→ 7,457 total

Companies

Recent Filings

Address

1119 ST. PAUL STREET

BALTIMORE, MD, 21202

View on SEC.gov